Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer - PubMed

Affiliations

• PMID: 24953238
• DOI: 10.1586/14737140.2014.915194

Review

Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer

Marcelo Garrido et al. Expert Rev Anticancer Ther. 2014 Aug.

Abstract

Chemotherapy prolongs survival in advanced gastric cancer (AGC). The challenges involved in this procedure are providing a framework to aid in determining the best single or combined chemotherapy protocols for targeted agents in front-line therapy for patients in a clinical setting. A review of Phase II-III studies published or referenced in major oncology congress publications from 1970 to 2013 was performed. Cisplatin and fluoropyrimidine remain the reference regimen. Fluoropyrimidine combined with oxaliplatin or irinotecan may also be employed in special situations. There are no comparative studies of the same regimens with or without anthacyclines; thus, the effectiveness of anthacyclines remains under debate. The introduction of trastuzumab in the front-line therapy of HER2-positive patients and ramucirumab in refractory patients ushered in an age of targeted therapy for this disease.

Keywords: 5-fluorouracil; advanced gastric cancer; chemotherapy; cisplatin; docetaxel; targeted agents; trastuzumab.

Similar articles

• Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review.

  Kuo HY, Yeh KH. Kuo HY, et al. Anticancer Res. 2014 Jul;34(7):3695-9. Anticancer Res. 2014. PMID: 24982389

• Geographic differences in approach to advanced gastric cancer: Is there a standard approach?

  Kim R, Tan A, Choi M, El-Rayes BF. Kim R, et al. Crit Rev Oncol Hematol. 2013 Nov;88(2):416-26. doi: 10.1016/j.critrevonc.2013.05.007. Epub 2013 Jun 10. Crit Rev Oncol Hematol. 2013. PMID: 23764501 Review.

• Current questions for the treatment of advanced gastric cancer.

  Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA. Cervantes A, et al. Cancer Treat Rev. 2013 Feb;39(1):60-7. doi: 10.1016/j.ctrv.2012.09.007. Epub 2012 Oct 25. Cancer Treat Rev. 2013. PMID: 23102520 Review.

• A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.

  Choi YH, Oh SC, Kim JS, Nam SH, Kim BS, Cho SH, Chung IJ, Song EK, Yim CY, Baek JH, Jeung HC, Hong YS, Yang SH, Kang HJ. Choi YH, et al. Cancer Chemother Pharmacol. 2012 Nov;70(5):665-72. doi: 10.1007/s00280-012-1956-1. Epub 2012 Aug 25. Cancer Chemother Pharmacol. 2012. PMID: 22926638 Clinical Trial.

• Docetaxel in the treatment of gastric cancer.

  Thuss-Patience PC, Kretzschmar A, Reichardt P. Thuss-Patience PC, et al. Future Oncol. 2006 Oct;2(5):603-20. doi: 10.2217/14796694.2.5.603. Future Oncol. 2006. PMID: 17026452 Review.

Cited by

• Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX.

  Oh SY, Shin A, Kim SG, Hwang JA, Hong SH, Lee YS, Kwon HC. Oh SY, et al. Oncotarget. 2016 May 24;7(21):31204-14. doi: 10.18632/oncotarget.9100. Oncotarget. 2016. PMID: 27144430 Free PMC article.

• Phase II trial of dacomitinib in patients with HER2-positive gastric cancer.

  Oh DY, Lee KW, Cho JY, Kang WK, Im SA, Kim JW, Bang YJ. Oh DY, et al. Gastric Cancer. 2016 Oct;19(4):1095-1103. doi: 10.1007/s10120-015-0567-z. Epub 2015 Nov 18. Gastric Cancer. 2016. PMID: 26581547 Clinical Trial.

• Joint detection of ERCC1, TUBB3, and TYMS guidance selection of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy in advanced gastric cancer patients.

  Luo Y, Li Z, Cui S, Shen C, Zhao J, Wu M, Li Y, Wang M, Chen R, Liu Z, Ri-Li G. Luo Y, et al. Eur J Med Res. 2014 Sep 16;19(1):50. doi: 10.1186/s40001-014-0050-z. Eur J Med Res. 2014. PMID: 25223338 Free PMC article. Retracted.

• Chemotherapy for advanced gastric cancer.

  Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Wagner AD, et al. Cochrane Database Syst Rev. 2017 Aug 29;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4. Cochrane Database Syst Rev. 2017. PMID: 28850174 Free PMC article. Review.

• HNRNPK inhibits gastric cancer cell proliferation through p53/p21/CCND1 pathway.

  Huang H, Han Y, Yang X, Li M, Zhu R, Hu J, Zhang X, Wei R, Li K, Gao R. Huang H, et al. Oncotarget. 2017 Oct 17;8(61):103364-103374. doi: 10.18632/oncotarget.21873. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262567 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal